Hoersholm, Denmark (Press Release) – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) today announced that the first patient has been in­cluded in the APO010 Screening Protocol for Multiple Myeloma by MPI's spinout OV. This patient has entered the study at the first out of four planned participating Danish hematology sites. Approximately 150 patients will be screened using MPI's DRP(TM) (Drug Response Predictor), out-licensed to Oncology Venture. The DRP(TM) uses genomic in­­for­ma­tion from the individual cancer patient's tumor. The screen­ing will identify 15 patients with the highest likelihood to benefit …